A2G2 is a glycan that functions as an antigen-binding molecule. It binds to the CD20 receptor on the surface of human B cells, which have a role in cancer and inflammatory disease development. A2G2 is produced by modifying endogenous molecules by adding galactose into the carbohydrate backbone.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
